GlassScriptPhysician profile
Ahmed A Khan
NPI 1639165277
$4,921.06
in general payments reported to CMS, 2019-2025
32 companies · $694 in 2025
The $694 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $497 · 2021: $726 · 2022: $472 · 2023: $1,158 · 2024: $841 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,493 · Travel and Lodging: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,493.39 |
| Travel and Lodging | $199.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $970.10 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $792.99 | 2019-2025 | Lifevest |
| Abiomed | $481.42 | 2021-2023 | Impella |
| Abbott Laboratories | $287.44 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Xience Skypoint, Aveir |
| Astrazeneca Pharmaceuticals LP | $264.71 | 2019-2024 | Farxiga, Brilinta |
| Medtronic, INC. | $262.60 | 2021-2024 | Evera Mri Xt Dr Surescan, In.Pact Admiral, Micra |
| Atricure, INC. | $252.73 | 2022-2024 | |
| Boston Scientific Corporation | $169.42 | 2024-2025 | Avvigo Guidance System, Eluvia, Bodyguardian |
| Actelion Pharmaceuticals US, INC. | $154.71 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Philips North America LLC | $138.91 | 2019-2025 | Coronary Other |
| Shockwave Medical, INC | $119.53 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Elutia, INC. | $115.43 | 2020-2022 | |
| Pfizer INC. | $111.33 | 2020-2024 | |
| Cardiovascular Systems INC. | $108.92 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $97.14 | 2019-2024 | Xarelto |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $90.10 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $47.96 | 2023-2024 | Uzedy, Austedo Xr |
| Medicomp INC | $46.87 | 2022 | |
| Lundbeck LLC | $43.90 | 2019 | |
| Allergan, INC. | $43.71 | 2020 | |
| Amgen INC. | $42.75 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $39.51 | 2023 | Arcalyst |
| Amarin Pharma, INC. | $38.32 | 2019-2021 | |
| Tactile Systems Technology INC | $33.73 | 2025 | Nimbl, Flexitouch Plus |
| Chiesi USA, INC. | $33.21 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.53 | 2020-2022 | |
| Daiichi Sankyo INC. | $19.67 | 2021 | |
| Merck Sharp & Dohme LLC | $19.27 | 2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $16.90 | 2023 | Camzyos |
| Sanofi-Aventis U.S. LLC | $16.74 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $14.74 | 2023 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $13.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.